English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/203056
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: Potential antitumour dual agents

AuthorsGonzález-Hernández, Elena; Aparicio, Rubén; Garayoa, Mercedes ; Montero, María J.; Sevilla, Mª Ángeles; Pérez-Melero, Concepción
Issue Date2019
PublisherRoyal Society of Chemistry (UK)
CitationMedChemComm 10: 1589-1598 (2019)
AbstractThe use of multitarget drugs has evolved as an alternative to “magic bullets” for the treatment of complex diseases such as cancer, in order to affect simultaneously several targets relevant to the disease. We have designed and synthesized a series of dual agents as both Eg5 inhibitors and calcium channel blockers, bearing a 4-aryldihydropyrimidine core. Compound 2 (aryl: 3-nitrophenyl) was selected as potential dual agent due to displaying both activities: it is a vasorelaxant agent (>90% relaxation at 10−5 M in KCl-precontracted aorta rings), it decreases the response to calcium and it is cytotoxic to MCF-7 (breast), HCT-116 (colon) and A-549 (lung) cancer cell lines. The dual mechanism of action was confirmed by blocking (−)-BAY K8644-induced vascular contraction and production of monopolar spindles, typical of Eg5 inhibition. Docking suggests that both (R) and (S)-enantiomers could bind Eg5.
Publisher version (URL)http://dx.doi.org/10.1039/c9md00108e
URIhttp://hdl.handle.net/10261/203056
DOI10.1039/c9md00108e
ISSN2040-2503
E-ISSN2040-2511
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.